<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139592">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01961882</url>
  </required_header>
  <id_info>
    <org_study_id>311-12-001</org_study_id>
    <nct_id>NCT01961882</nct_id>
  </id_info>
  <brief_title>A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea Otsuka Pharmaceutical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <authority>Taiwan : Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare disease-free survival in patients 60 years or older with acute myeloid leukemia
      (AML) who are randomly assigned to receive either OCV-501 monotherapy or placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Disease-Free Survival</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>OCV-501 arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCV-501</intervention_name>
    <arm_group_label>OCV-501 arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with AML who achieved first complete remission within one or two courses of
             standard induction therapy, and completed standard consolidation therapy (more than
             one course).

          -  Patients who are 60 years or older.

          -  Patients who have provided written informed consent within 90 days from the last dose
             of consolidation therapy on an informed consent form that has been approved by an
             institutional review board or independent ethics committee.

        Exclusion Criteria:

          -  Patients who have acute promyelocytic leukemia (APL) with t(15;17) (q22;q12),
             (PML/RARA) karyotype abnormalities, and other variant types.

          -  Patients who are scheduled for hematopoietic stem cell transplantation.

          -  Patients who have received drugs potentially affecting the immune system within 4
             weeks before starting IMP administration or who may receive such drugs after start of
             the trial.

          -  Patients who have a severe concurrent disease or psychiatric illness likely to
             interfere with participation in this trial.

          -  Patients who are HIV antibody positive, HBV-DNA positive or HCV antibody positive.

          -  Patients judged to be ineligible by the investigator (or subinvestigator) for any
             other reasons.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoji Imaoka, Mr</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7314</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Kanto Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 28, 2014</lastchanged_date>
  <firstreceived_date>October 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OCV-501</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Antigen specific cancer immunotherapeutic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
